Market Place
Sourcing Support
Merck`s KEYTRUDA Demonstrates 10-Year Survival Benefit In Melanoma
15 Sep 2024 //
BUSINESSWIRE
BMS Shows 10-Year Survival Data For Opdivo-Yervoy In Advanced Melanoma
15 Sep 2024 //
BUSINESSWIRE
Ultimovacs Updates On UV1 Phase II NIPU Trial At ESMO 2024
08 Sep 2024 //
GLOBENEWSWIRE
BMS Receives FDA sBLA Acceptance For Hepatocellular Carcinoma Drug
22 Aug 2024 //
BUSINESSWIRE
BMS gains EMA validation for Opdivo/Yervoy combo in liver cancer
20 Jul 2024 //
PRESS RELEASE
Bristol Myers Squibb Receives EMA Validation For Opdivo Plus Yervoy
19 Jul 2024 //
BUSINESSWIRE
ASCO: Bristol calls Roche and AZ`s bets in 1L liver cancer
04 Jun 2024 //
FIERCE PHARMA
BMS` triplet, Iovance`s Amtagvi-Keytruda target melanoma
24 May 2024 //
FIERCE PHARMA
EMA Validates BMS’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab)
06 May 2024 //
PRESS RELEASE
Bristol Myers Squibb`s Opdivo application validated by EMA.
06 May 2024 //
BUSINESSWIRE
Ultimovacs lays off 40% in wake of cancer vaccine`s phase 2 fail
17 Apr 2024 //
FIERCE BIOTECH
Bristol Myers` Opdivo-Yervoy combo meets main goal in liver cancer trial
21 Mar 2024 //
REUTERS
Ultimovacs Announces Results from INITIUM Study Evaluating UV1 Vaccination
07 Mar 2024 //
GLOBENEWSWIRE
BMS`s Opdivo-Yervoy excels in first-line colorectal cancer trial
08 Dec 2023 //
FIERCE PHARMA
BMS Announces Phase 3 Trial Evaluating Opdivo in Microsatellite Instability
07 Dec 2023 //
BUSINESSWIRE
Neoadjuvant Nivolumab/Ipilimumab Combo Elicits Responses in Resectable HCC
13 Sep 2023 //
ONCLIVE
Phase 3 Show Survival with Opdivo Plus Yervoy in First-Line Treatment for NSCLC
11 Sep 2023 //
BUSINESSWIRE
BMS, AZ settle cancer immunotherapy patent suits for $510M
02 Aug 2023 //
FIERCE PHARMA
Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable Survival
04 Jun 2023 //
BUSINESSWIRE
Regeneron`s Libtayo delivers lung cancer win with BMS` Yervoy
02 Dec 2022 //
FIERCEPHARMA
Bristol`s Biologic Yervoy (Ipilimumab) Receives Approval in the U.S.
23 Nov 2022 //
FDA
Intensity Reports Use of INT230-6 Alone or Combination with Ipilimumab Shows
18 Nov 2022 //
PRNEWSWIRE
Exelixis Announces Results from PIII COSMIC-313 Pivotal Trial in Patients
07 Sep 2022 //
BUSINESSWIRE
NICE issues positive appraisal document for advanced kidney cancer treatment
22 Aug 2022 //
PHARMAFILE
BMS` combo hits a roadblock in PhIII kidney test
30 Jul 2022 //
ENDPTS
First immunotherapy for untreated, unresectable malignant pleural mesothelioma
14 Jul 2022 //
PHARMAFILE
Exelixis trots out triplet kidney cancer win
12 Jul 2022 //
FIERCEPHARMA
Landmark Five-Year Data from PIII CheckMate -227 Trial
06 Jun 2022 //
BUSINESSWIRE
BMS` Opdivo wins dual FDA nods in esophageal cancer
01 Jun 2022 //
FIERCEPHARMA
BMS` Opdivo-Yervoy combo flopped in first-line bladder cancer
17 May 2022 //
SEEKING ALPHA
Bristol Myers Biologic Yervoy (Ipilimumab) Receives Approval in the U.S.
11 May 2022 //
FDA
Agilent Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include ESCC
05 Apr 2022 //
BUSINESSWIRE
NICE recommends new combination for untreated advanced kidney cancer
04 Feb 2022 //
PHARMAFILE
TRACON Announces Positive Results from IDMC Review from Ongoing ENVASARC Trial
27 Dec 2021 //
GLOBENEWSWIRE
Exelixis Initiates Phase 1b Trial of XL092 with Immuno-oncology Therapies
15 Dec 2021 //
BUSINESSWIRE
Opdivo wins Japanese nod for gastric, oesophageal cancer indications
26 Nov 2021 //
FIRSTWORDPHARMA
TCR² TherapAnnounces Clinical Trial Collaboration Agreement with Bristol Myers
25 Oct 2021 //
GLOBENEWSWIRE
BMS, GRYT push for diversity in oncology with new initiative
25 Oct 2021 //
FIERCEPHARMA
BeyondSpring Announces First Patient Treated in Phase 2 Study with Plinabulin
21 Oct 2021 //
PRESS RELEASE
Opdivo-Yervoy flops 2 stomach cancer trials
20 Sep 2021 //
FIERCEPHARMA
Gritstone Announces Positive Clinical Data with GRANITE during ESMO 2021
17 Sep 2021 //
GLOBENEWSWIRE
Gritstone Dosed of 1st Solid Tumor Patient with Neoantigen Immunotherapy
17 Sep 2021 //
GLOBENEWSWIRE
Applications Submitted for Combination Therapy of Opdivo + Yervoy in Japan
14 Sep 2021 //
PRESS RELEASE
BMS’ Opdivo combo offers survival benefits in Phase III mesothelioma trial
14 Sep 2021 //
CLINICALTRIALSARENA
Opdivo Plus Yervoy Demonstrates Overall Survival in PIII CheckMate -743 Trial
13 Sep 2021 //
BUSINESSWIRE
Opdivo Received Approval to Expand its Use in Combination with Yervoy in Taiwan
08 Sep 2021 //
PRESS RELEASE
Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits
08 Sep 2021 //
BUSINESSWIRE
EMA validates BMS’s Applications for Opdivo+ Yervoy and Opdivo + Chemotherapy.
17 Aug 2021 //
BUSINESSWIRE
BMS Receives European Commission Approval for Opdivo Plus Yervoy (ipilimumab)
29 Jun 2021 //
ONCLIVE
BMS Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy
29 Jun 2021 //
BUSINESSWIRE
ImmunoGenesis Announces Publication of Phase 1 Data in Advanced Cancer
16 Jun 2021 //
PRNEWSWIRE
Final Data from Calithera Biosciences’ Ph2 CANTATA Study Presented at 2021 ASCO
07 Jun 2021 //
GLOBENEWSWIRE
Osel Announces Positive Results from Ph1b Trial of CBM588 & CheckPoint Inhibitor
07 Jun 2021 //
BUSINESSWIRE
#ASCO21: Bristol Myers` solo, dual I/O regimens best chemo alone
03 Jun 2021 //
ENDPTS
NICE `no` for Opdivo/Yervoy lung cancer combo
08 Apr 2021 //
PHARMATIMES
Xilio raises $95M to take twists on Yervoy and IL-2 into clinic
24 Feb 2021 //
FIERCE BIOTECH
